PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

被引：0
|
作者：
Yael Babichev
Leah Kabaroff
Alessandro Datti
David Uehling
Methvin Isaac
Rima Al-awar
Michael Prakesch
Ren X. Sun
Paul C. Boutros
Rosemarie Venier
Brendan C. Dickson
Rebecca A. Gladdy
机构：
[1] Mount Sinai Hospital,Lunenfeld
[2] Lunenfeld-Tanenbaum Research Institute,Tanenbaum Research Institute
[3] University of Perugia,Sinai
[4] Ontario Institute for Cancer Research,McLaughlin Assay and Robotic Technologies Facility
[5] University of Toronto,Department of Agricultural, Food, and Environmental Sciences
[6] Ontario Institute for Cancer Research,Drug Discovery Group
[7] University of Toronto,Department of Pharmacology and Toxicology
[8] Mount Sinai Hospital,Informatics and Biocomputing Program
[9] University of Toronto,Department of Medical Biophysics
[10] University of Toronto,Department of Pathology and Laboratory Medicine
[11] Ontario Institute for Cancer Research,Department of Surgery
[12] Lunenfeld-Tanenbaum Research Institute,Institute of Medical Science
来源：
Journal of Translational Medicine | / 14卷
关键词：
Leiomyosarcoma; PI3K; mTOR; Drug discovery; Sarcoma; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis
    Chen, Jiezhong
    Crawford, Ross
    Xiao, Yin
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (02) : 245 - 249
  • [12] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis Reply
    Matsuzaki, Sachiko
    Pouly, Jean-Luc
    Canis, Michel
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3628 - 3629
  • [13] MEK inhibition in combination with PI3K/AKT/MTOR is a promising therapeutic in basal bladder cancer.
    Apfel, Athena M.
    Merrill, Nathan M.
    Vandecan, Nathalie M.
    Bao, Liwei
    Cheng, Xu
    Lopez-Barcons, Lluis A.
    Day, Kathleen C.
    Palmbos, Phillip L.
    Day, Mark L.
    Udager, Aaron M.
    Soellner, Matthew B.
    Merajver, Sofia D.
    CANCER RESEARCH, 2021, 81 (13)
  • [14] Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
    Bhatt, Aadra P.
    Bhende, Prasanna M.
    Sin, Sang-Hoon
    Roy, Debasmita
    Dittmer, Dirk P.
    Damania, Blossom
    BLOOD, 2010, 115 (22) : 4455 - 4463
  • [15] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [16] PI3K/AKT/mTOR pathway in angiogenesis
    Karar, Jayashree
    Maity, Amit
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2011, 4
  • [17] Overview of the PI3K/Akt/mTOR pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2008, 19 : 21 - 21
  • [18] The PI3K/AKT/mTOR interactive pathway
    Ersahin, Tulin
    Tuncbag, Nurcan
    Cetin-Atalay, Rengul
    MOLECULAR BIOSYSTEMS, 2015, 11 (07) : 1946 - 1954
  • [19] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [20] PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
    Zhu, Kunrui
    Wu, Yanqi
    He, Ping
    Fan, Yu
    Zhong, Xiaorong
    Zheng, Hong
    Luo, Ting
    CELLS, 2022, 11 (16)
12345